Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;89(1):171-173.
doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5.

Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus

François Chasset  1 , Léa Jaume  2 , Alexis Mathian  3 , Noémie Abisror  4 , Amélie Dutheil  2 , Annick Barbaud  2 , Diane Kottler  5 , Céline Girard  6 , Sandrine Jousse-Joulin  7 , Marie Tauber  8 , Cristina Bulai Livideanu  9 , Véronique Avettand-Fenoel  10 , Raphael Lhote  3 , Micheline Pha  3 , Zahir Amoura  3 ; EMSED (Etude des maladies systémiques en dermatologie) study group
Affiliations

Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus

François Chasset et al. J Am Acad Dermatol. 2023 Jul.
No abstract available

Keywords: anifrolumab; belimumab; cutaneous lupus erythematosus; refractory; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Chasset received grant/research support from AstraZeneca; participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, and Principabio; and received speaking fees and honoraria from AstraZeneca and GSK. Dr Mathian has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca and GSK; and received consulting fees, speaking fees, and honoraria from AstraZeneca, GSK, Otsuka, and Novartis. Dr Livideanu received speaking fee and honoraria from Blueprint Medicine, Lilly, and UCB and participated in advisory board for AbbVie, Boehringer Ingelheim, Blueprint Medicine, and UCB. Dr Avettand-Fenoel received grant/research support and speaking fees from Gilead and ViiV Healthcare. Dr Amoura has received grant/research support from GSK, AstraZeneca, Roche, Novartis, and Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, and Otsuka; and received consulting fees, speaking fees, and honoraria from AstraZeneca and GSK. Drs Jaume, Abisror, Dutheil, Barbaud, Kottler, Girard, Jousse-Joulin, Tauber, Lhote, and Pha have no conflicts of interest to declare.

MeSH terms

Substances